Can New Bone Be Made From Skin Stem Cells?
Cartilage can be made from skin stem cells and now bone! In this video, Sharecare expert Michael Roizen, MD, chief wellness officer for Cleveland Clinic, exp...

By: SharecareVideo

See original here:
Can New Bone Be Made From Skin Stem Cells? - Video

Stem Cell Therapy Docere Clinics

By: KeysToYoungerLiving

Continue reading here:
Stem Cell Therapy Docere Clinics - Video

DUBLIN, July 18, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/qc7zk2/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Stem Cell Research in Asia-Pacific a Growth Engine for Region's Scientific Ambitions

The stem cell therapy market in Asia-Pacific is poised to offer significant contributions in the future, thanks to renewed interest by the respective governments of India, China, Japan, South Korea and Singapore to provide cures for a range of diseases, states a new report by healthcare experts GBI Research.

Stem cells are unique body cells that possess the ability to divide and differentiate into diverse cell types, and can be used to produce more stem cells. The use of adult stem cells has been successfully employed to treat bone and blood related disorders such as leukemia, through bone marrow transplants. Stem cell therapy is used to repair and regenerate the damaged tissue, though the actual mechanism of action is largely unknown.

The growth in the stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries' Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a new growth engine for the nation's economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohn's disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research.

Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to GBI Research's analysis of the stem cell therapy research in Asia-Pacific, 63% of pipeline molecules were being researched by academia. The emergence of institutional research has boosted stem cell discoveries, as companies can be put off conducting research due to uncertain therapeutic outcomes. China and Japan witness only a negligible industry presence in stem cell research, as academic institutions dominate - however in contrast, India has the presence of both industry and academia. The major institutions engaged in stem cell research in India are LV Prasad Eye Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate Institute of Medical Education and Research (PGIMER) for stem cell therapy for type 2 diabetes mellitus.

The market is poised for significant growth in the future, due to the anticipated launch of JCR Pharmaceuticals' JR-031 in Japan in 2014, and FCB Pharmicell's Cerecellgram (CCG) in South Korea in 2015. GBI Research therefore predicts that the stem cell therapy market will grow in value from $545m in 2012 to $972m in 2018, at a Compound Annual Growth Rate (CAGR) of 10%.

See the original post here:
Stem Cell Therapy Market in Asia-Pacific to 2018

Avascular necrosis treatment with bone marrow stem cells.
Avascular necrosis treatment with stem cells from bone marrow. Visit http://www.blog.hipsurgery.in to get details of types of treatment. Visit http://www.hipsurgery...

By: ALAMPALLAM VENKATACHALAM

Excerpt from:
Avascular necrosis treatment with bone marrow stem cells. - Video

Freeport, Bahamas (PRWEB) July 17, 2013

Okyanos Heart Institute, whose mission it is to bring a new standard of care and better quality of life to patients with coronary artery disease using cardiac stem cell therapy, has named Leslie Miller, M.D., F.A.C.C. as its chief science officer. Dr. Miller is a leading heart failure specialist and experienced thought leader in cardiac stem cell therapy. He is director of the University of South Florida (USF) Heart Institute, professor of cardiovascular sciences at the USF Health Morsani College of Medicine, and was formerly the director of cardiology at Georgetown University. Dr. Miller has been an investigator in over 80 clinical trials.

The use of adult stem cells derived from adipose (fat) tissue to treat congestive heart failure has the potential to change the game for the millions of patients suffering from this disease, said Miller. These stem and regenerative cells have been shown to stimulate the growth of new blood vessels, are anti-inflammatory and prevent at-risk cells from dying. These combined mechanisms can provide important therapeutic benefit to heart failure patients.

As a current member of Okyanos medical advisory council, Dr. Miller has actively advised us on patients criteria for cardiac stem cell therapy, says Okyanos Chief Medical Officer Howard Walpole. In this additional role as Chief Science Officer, he will be evaluating new research protocols and reporting on findings from the patient registry that will help advance the field of cardiac stem cell therapy. His experience and track record in leading academic research is outstanding. This integrated approach in research and clinical application in The Bahamas makes Okyanos Heart Institute one of the first places patients can receive new treatments.

Dr. Leslie Miller is a well-respected visionary in the field of cardiovascular disease says Okyanos CEO Matt Feshbach. This role will further advance our quality measures and the structure of our patient registry. We look forward to his contribution to improving the lives of patients using adult stem cells derived from their own fat tissue who, up until now, have exhausted their options with conventional treatments.

ABOUT OKYANOS HEART INSTITUTE: (Oh key AH nos) Based in Freeport, The Bahamas, Okyanos Heart Institutes mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.A.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from ones own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive catheterization, stimulates the growth of new blood vessels, a process known as angiogenesis. The treatment facilitates blood flow in the heart and supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos (Oceanos) symbolizes flow. For more information, go to http://www.okyanos.com/.

NEW MEDIA CONTENT: Okyanos LinkedIn page: http://www.linkedin.com/company/okyanos-heart-institute

Okyanos Facebook page: https://www.facebook.com/OKYANOS

Okyanos Twitter page: https://twitter.com/#!/OkyanosHeart

END

See the original post here:
Dr. Leslie Miller Named Chief Science Officer of Okyanos Heart Institute's Cardiac Stem Cell Therapy Treatment for ...

Stem Cell Therapy Treatment for Idiopathic Polymyositis by Dr Alok Sharma, Mumbai, India.
Improvement seen in just 5 day after Stem Cell Therapy Treatment for Idiopathic Polymyositis by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Fle...

By: Neurogen Brain and Spine Institute

More here:
Stem Cell Therapy Treatment for Idiopathic Polymyositis by Dr Alok Sharma, Mumbai, India. - Video

Stem Cell Therapy Treatment for Left Hemiplegic Cerebral Palsy by Dr Alok Sharma, Mumbai, India.
Improvement seen in just 5 day after Stem Cell Therapy Treatment for Left Hemiplegic Cerebral Palsy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy...

By: Neurogen Brain and Spine Institute

Read this article:
Stem Cell Therapy Treatment for Left Hemiplegic Cerebral Palsy by Dr Alok Sharma, Mumbai, India. - Video

Stem Cell Therapy Treatment for Autism by Dr Alok Sharma, Mumbai, India. Part 2
Improvement seen in just 7 months after Stem Cell Therapy Treatment for Autism by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Emotional respons...

By: Neurogen Brain and Spine Institute

Visit link:
Stem Cell Therapy Treatment for Autism by Dr Alok Sharma, Mumbai, India. Part 2 - Video

Stem Cell Therapy Treatment for Cerebral Atrophy by Dr Alok Sharma, Mumbai, India. Part 2
Improvement seen in just 5 day after Stem Cell Therapy Treatment for Cerebral Atrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Ball throw...

By: Neurogen Brain and Spine Institute

Continue reading here:
Stem Cell Therapy Treatment for Cerebral Atrophy by Dr Alok Sharma, Mumbai, India. Part 2 - Video

DUBLIN, July 16, 2013 /PRNewswire/ --

Research and Markets ( http://www.researchandmarkets.com/research/dhdp3r/cell_therapy) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets were analyzed for 2012, and projected to 2022. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 287 of these are profiled in part II of the report along with tabulation of 273 alliances. Of these companies, 158 are involved in stem cells. Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 55 Tables and 12 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

Read more here:
Cell Therapy - Technologies, Markets and Companies - Updated 2013 with New Companies and Profiles

stem cell therapy for Sports injuries.
Videos is about the Stem Cell Treatment provided to various athletes and sports persons. Dr. Purita had provided treatment for the knee, elbow, shoulder, wri...

By: Stem Md

Read the original here:
stem cell therapy for Sports injuries. - Video

Life stem cell therapy Purtier
9 years old girl benefited from deer placenta.

By: Keith Chew

Continued here:
Life stem cell therapy Purtier - Video

Wisconsin Alumni Research Foundation ranks fourth in biotechnology patents 77Square.com Bioentrepreneur, a website affiliated with the journal Nature, has ranked UW-Madison's Wisconsin Alumni Research Foundation (WARF) the fourth-most-active entity in biotechnology patents issued in the U.S. and Europe from 2008 to 2012. In that span ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGQOLEBzDDMnFMht0qfe1OUoFdLNg&url=http://host.madison.com/wsj/news/local/education/university/wisconsin-alumni-research-foundation-ranks-fourth-in-biotechnology-patents/article_ceb5524f-8c64-5bae-98d4-5fd7e9450524.html

Boston Globe

Is Alynlam the next breakthrough name in biotechnology? Investors say 'yes' MedCity News (Reuters) - A radical new treatment for genetic disorders has catapulted Alnylam Pharmaceuticals Inc into the crosshairs of investors seeking the next breakthrough name in biotechnology. The challenge for the Cambridge, Massachusetts-based company ... Stocks to Keep Your Eyes on - Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN ...Techsonian Alnylam Pharmaceuticals (ALNY) Shares Soar After Positive Drug Trial ResultsNew Stuff Here Alnylam Reports Positive Top-Line Results for ALN-TTRsc, a Subcutaneously ...EON: Enhanced Online News (press release) all 32 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEz5ensUYZAz22zl7md7KPcZtVDCQ&url=http://medcitynews.com/2013/07/is-alynlam-the-next-breakthrough-name-in-biotechnology-investors-say-yes/

ThyssenKrupp inaugurated biotechnology in Leuna SteelGuru Dr. Heinrich Hiesinger CEO of ThyssenKrupp said that “Modern biotechnology is one of the key technologies of the 21st century. Biotechnological processes, products and services play a role in almost all areas of our daily lives for example in the ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFOL_CVTfJ5-xATaVosty46SZpARQ&url=http://www.steelguru.com/international_news/ThyssenKrupp_inaugurated_biotechnology_in_Leuna/318694.html

The Express Tribune

Genetic Engineering, Biotechnology and the Future Of Humanity Center for Research on Globalization In the UK, Genewatch UK has revealed how Monsanto, Syngenta, Bayer, and BASF (all biotech companies) under the guise of the 'Agricultural Biotechnology Council' held a meeting in June 2012 with government ministers and academics to formulate a ... Agricultural sector promotes biotechnologyThe Express Tribune Food Minister for using biotechnology to reduce food insecurityPakistanToday.com.pk all 6 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNH-TAOiYDgt-zLnE1DtCjTTRd-oxA&url=http://www.globalresearch.ca/genetic-engineering-biotechnology-and-the-future-of-humanity/5342175

First microRNA mimic enters clinic Nature.com Nature Biotechnology. Full text access provided to Google by Bot. Cart. Search Go Advanced search · nature.com · journal home · current issue · News; full text. Nature Biotechnology | News. Print; Email; Share/bookmark. Cite U Like · Facebook · Twitter ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEWC47_z_Yfzc3MAnDapCvGvlkARQ&url=http://www.nature.com/nbt/journal/v31/n7/full/nbt0713-577.html

Common food supplement fights degenerative brain disorders Heritage Florida Jewish News A team headed by professor Gil Ast and Dr. Ron Bochner of Tel Aviv University's department of human molecular genetics decided to test whether the same chemical, which is naturally synthesized in the body and known to boost memory capability, could ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGB0hFEVhN5otgMVSVBw3NoLDFzgg&url=http://www.heritagefl.com/story/2013/07/12/features/common-food-supplement-fights-degenerative-brain-disorders/1054.html

Study cracks universal RNA code, suggests a new cause for autism Phys.Org "This was a surprising finding, because we knew RBFOX1 controls gene expression, but had no idea it also stabilizes RNA," said Tim Hughes, a Professor in the Department of Molecular Genetics and the Donnelly Centre. "It's a good example of the ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNG5CdrVKBW-YXAYzsj6bvD5o9eKcA&url=http://phys.org/wire-news/135086764/study-cracks-universal-rna-code-suggests-a-new-cause-for-autism.html

BioNews Texas

UT Southwestern Medical Center Scientists' Discovery Of Rare Gene Mutation ... BioNews Texas ... Development, UT Southwestern and Investigator, Howard Hughes Medical Institute, UT Southwestern; and Dr. Helen H. Hobbs, Professor, Department of Medicine Department of Molecular Genetics at the University of Texas Southwestern Medical Center in ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHnzOaBoXQjWRlw2V8NzRZARxfTwA&url=http://bionews-tx.com/news/2013/07/12/ut-southwestern-medical-center-scientists-discovery-of-rare-gene-mutation-ignites-anti-cholesterol-drug-development-race/